Corpus Intelligence IC Memo — GEISINGER WYOMING VALLEY MED CTR 2026-04-26 04:03 UTC
IC Memo — GEISINGER WYOMING VALLEY MED CTR
Investment Committee Memorandum | PA | 309 beds | Grade B | EBITDA uplift $57.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

GEISINGER WYOMING VALLEY MED CTR

CCN 390270 | LUZERNE, PA | 309 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

GEISINGER WYOMING VALLEY MED CTR is a 309-bed suburban community hospital in LUZERNE, PA with $782.7M in net patient revenue and a 5.9% operating margin. The hospital serves a payer mix of 27.6% Medicare, 3.1% Medicaid, and 69.3% commercial.

Thesis: Platform Growth. Our ML models identify $57.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 5.9% to 13.3% (+736bps).

Net Revenue HCRIS$782.7M
Current EBITDA COMPUTED$46.6M
Operating Margin COMPUTED5.9%
Occupancy HCRIS80.9%
Revenue / Bed COMPUTED$2.5M
Net-to-Gross HCRIS12.6%
Distress Probability ML37.7%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
65
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of 5.9% places it above the state median. Among 65 size-comparable peers (154-618 beds), the median margin is -7.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (154-618), prioritizing same-state peers. 65 hospitals in the comp set.

HospitalStateBedsRevenueMargin
GEISINGER WYOMING VALLEY MED C (Target)PA309$782.7M5.9%
MILTON S. HERSHEY MEDICAL CENTPA616$2.08B-2.8%
GEISINGER MEDICAL CENTERPA525$1.58B4.1%
YORK HOSPITALPA533$1.47B9.7%
UPMC PINNACLE HOSPITALSPA561$1.29B8.9%
READING HOSPITAL AND MEDICAL CPA561$1.15B6.1%
PRESBYTERIAN MEDICAL CENTERPA328$988.5M-18.9%
ALLEGHENY GENERAL HOSPITALPA528$919.7M-0.1%
UPMC MAGEE-WOMENS HOSPITALPA347$910.8M-23.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $57.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$16.4M+210bp18mo
Cost to Collect4.5%2.5%$15.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$15.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$9.5M+122bp9mo
Clean Claim Rate88.0%96.0%$501K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$16.4M
Cost to Collect
$15.7M
Denial Rate Reduction
$15.5M
A/R Days Reduction
$9.5M
Clean Claim Rate
$501K
Total EBITDA Uplift$57.6M
Current EBITDA$46.6M
+ RCM Uplift+$57.6M
Pro Forma EBITDA$104.2M
Current Margin5.9%
Pro Forma Margin13.3%
WC Released (1x)$30.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$71.6M$883.4M12.33x65.3%
Base (11x exit)10.0x11.0x$71.6M$995.0M13.89x69.2%
Bull Case9.0x11.0x$64.5M$1.21B18.74x79.7%
Bull (12x exit)9.0x12.0x$64.5M$1.34B20.74x83.4%
Bear Case11.0x10.0x$78.8M$572.0M7.26x48.6%
Bear (11x exit)11.0x11.0x$78.8M$654.8M8.31x52.7%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 65 hospitals with 154-618 beds
  • Same-state prioritization (n=66)
  • Comp margins: P25=-17.9% / P50=-7.6% / P75=-0.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.